Metabolic syndrome across Europe: different clusters of risk factors
Walking away from it makes a huge difference, not just for your lips but for your entire skin health
Can Mounjaro cause stomach paralysis
Research suggests that it also contributes to cytoprotective processes by enhancing cellular resistance to chemical, mechanical, or ischemic stress
9.4 Alcohol and Its Effects on Glycemic Control Alcohol consumption may exacerbate glycemic variability and should be approached cautiously
Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear